Definium Therapeutics News - October 9, 2026
JPMorgan Bets Big on Definium's Brain Drug — But Can a Small Biotech Really Double From Here?
Shares of Definium Therapeutics surged 10.2% to $37.65 on October 9 after JPMorgan initiated coverage with an Overweight rating and an $84 price target —...
🟢 Definium Therapeutics is trading 10% up today after JPMorgan initiated coverage with an Overweight rating
Definium Therapeutics is trading at $37.65 (+10.15%) after JPMorgan initiated coverage with an Overweight rating. - JPMorgan set an $84 price target and...
🟢 Definium Therapeutics rises 4.2% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🟢 Definium Therapeutics is trading 4.04% up in pre-market amid broad-market strength that may support the move
Definium Therapeutics is trading at $35.56 (+4.04%) in pre-market, with broad-market strength potentially supporting the move, though no direct link is...